Recently, the use of metal-on-metal articulations in total hip arthroplasty (THA) has led to an increase in adverse events owing to local soft-tissue reactions from metal ions and wear debris. While the majority of these implants perform well, it has been increasingly recognised that a small proportion of patients may develop complications secondary to systemic cobalt toxicity when these implants fail. However, distinguishing true toxicity from benign elevations in cobalt ion levels can be challenging.

The purpose of this two part series is to review the use of cobalt alloys in THA and to highlight the following related topics of interest: mechanisms of cobalt ion release and their measurement, definitions of pathological cobalt ion levels, and the pathophysiology, risk factors and treatment of cobalt toxicity. Historically, these metal-on-metal arthroplasties are composed of a chromium-cobalt articulation.

The release of cobalt is due to the mechanical and oxidative stresses placed on the prosthetic joint. It exerts its pathological effects through direct cellular toxicity.

This manuscript will highlight the pathophysiology of cobalt toxicity in patients with metal-on-metal hip arthroplasties.

Take home message: Patients with new or evolving hip symptoms with a prior history of THA warrant orthopaedic surgical evaluation. Increased awareness of the range of systemic symptoms associated with cobalt toxicity, coupled with prompt orthopaedic intervention, may forestall the development of further complications.

Cite this article: Bone Joint J 2016;98-B:6–13.

As adverse events related to metal on metal hip arthroplasty have been better understood, there has been increased interest in toxicity related to the high circulating levels of cobalt ions. However, distinguishing true toxicity from benign elevations in cobalt levels can be challenging. The purpose of this review is to examine the use of cobalt alloys in total hip arthroplasty, to review the methods of measuring circulating cobalt levels, to define a level of cobalt which is considered pathological and to review the pathophysiology, risk factors and treatment of cobalt toxicity. To the best of our knowledge, there are 18 published cases where cobalt metal ion toxicity has been attributed to the use of cobalt-chromium alloys in hip arthroplasty. Of these cases, the great majority reported systemic toxic reactions at serum cobalt levels more than 100 μg/L. This review highlights some of the clinical features of cobalt toxicity, with the goal that early awareness may decrease the risk factors for the development of cobalt toxicity and/or reduce its severity.

Take home message: Severe adverse events can arise from the release of cobalt from metal-on-metal arthroplasties, and as such, orthopaedic surgeons should not only be aware of the presenting problems, but also have the knowledge to treat appropriately.

Cite this article: Bone Joint J 2016;98-B:14–20.

Revision of fractured ceramic-on-ceramic total hip replacements with a cobalt-chromium (CoCr) alloy-on-polyethylene articulation can facilitate metallosis and require further expensive revision surgery [1–3]. In the present study, a fifty-two year old male patient suffered from fatal cardiomyopathy after undergoing revision total hip arthroplasty. The patient had received a polyethylene-ceramic acetabular liner and a ceramic femoral head as his primary total hip replacement. The polyethylene-ceramic sandwich acetabular liner fractured in vivo after 58 months and the patient underwent his first revision surgery where he received a Vitamin E stabilized acetabular Polyethylene (PE) liner and a CoCr alloy femoral head with documented synovectomy at that time. After 15 months, the patient was admitted to hospital in cardiogenic shock, with retrieval of the bearing components. Before the second revision surgery, peak serum cobalt levels measured 6,521 μg/L, 78-times greater than serum cobalt levels of 83μg/L associated with cobalt poisoning [4]. Serum titanium levels found in the patient measured 17.5 μg/L) normal, healthy range 0–1.4 μg/L). The retrieved CoCr alloy femoral head had lost a total of 28.3g (24% or an estimated amount of 102 × 10⁻⁹ wear particles (∼2 μm diameter) [1]) within 16 months of in vivo service. Despite initiating a cobalt chelating therapy, the patients' cardiac left ventricular ejection fraction remained reduced at 6%. This was followed by multi-organ failure, and ultimately the patient passed away shortly after being taken off life support. Embedded ceramic particles were found on the backside and articular surfaces of the Vitamin E-stabilized PE acetabular liner. Evidence of fretting wear on the titanium (Ti) alloy acetabular shell was present, possibly explaining the increased serum Ti levels. Scanning electron microscopy and energy dispersive X-ray analyses confirmed Ti alloy transfer on the embedded ceramic particles on the backside PE liner surface and CoCr alloy transfer on the embedded ceramic particles on the articular PE liner surface. A fractured ceramic-on-ceramic total hip replacement should not be revised to a CoCr alloy-on-polyethylene articulation irrespective of concurrent synovectomy [5] as it can cause severe, third-body wear to the CoCr alloy femoral head that can lead to metallosis with fatal, systemic consequences.

Symptomatic cobalt toxicity from a failed total hip replacement is a rare but devastating complication. It has been reported following revision of fractured ceramic components, as well as in patients with failed metal-on-metal articulations. Potential clinical findings include fatigue, weakness, hypothyroidism, cardiomyopathy, polycythaemia, visual and hearing impairment, cognitive dysfunction, and neuropathy. We report a case of an otherwise healthy 46-year-old patient, who developed progressively worsening symptoms of cobalt toxicity beginning approximately six months following synovectomy and revision of a fractured ceramic-on-ceramic total hip replacement to a metal-on-polyethylene bearing. The whole blood cobalt levels peaked at 6521 µg/l. The patient died from cobalt-induced cardiomyopathy. Implant retrieval analysis confirmed a loss of 28.3 g mass of the cobalt–chromium femoral head as a result of severe abrasive wear by ceramic particles embedded in the revision polyethylene liner. Autopsy findings were consistent with heavy metal-induced cardiomyopathy.

We recommend using new ceramics at revision to minimise the risk of wear-related cobalt toxicity following breakage of ceramic components.

Cite this article: Bone Joint J 2013;95-B:31–7.